Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F.M. Ariëns; Jorien van der Schaft; Lotte S. Spekhorst; Daphne S. Bakker; Geertruida L.E. Romeijn; Tessa A. Kouwenhoven; Marijke Kamsteeg; Angelique N. Voorberg; Albert J. Oosting; Ilona de Ridder; Annemieke Sloeserwij; Inge Haeck; Judith L. Thijs; Marie L.A. Schuttelaar; Marjolein S.  de Bruin-Weller

doi:10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F.M. Ariëns^*
, Jorien van der Schaft
, Lotte S. Spekhorst
, Daphne S. Bakker
, Geertruida L.E. Romeijn
, Tessa A. Kouwenhoven
, Marijke Kamsteeg
, Angelique N. Voorberg
, Albert J. Oosting
, Ilona de Ridder
, Annemieke Sloeserwij
, Inge Haeck
, Judith L. Thijs
, Marie L.A. Schuttelaar
, Marjolein S. de Bruin-Weller^*

^*Corresponding author for this work

Public Health Research (PHR)

Research output: Contribution to journal › Article › Academic › peer-review

85 Citations (Scopus)

654 Downloads (Pure)

Abstract

Background
Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.

Objective
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.

Methods
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.

Results
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.

Limitations
Because of the lack of a control group and observational design, factors of bias may have been induced.

Conclusion
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

Original language	English
Pages (from-to)	e279-e280
Number of pages	10
Journal	Journal of the American Academy of Dermatology
Volume	84
Issue number	4
DOIs	https://doi.org/10.1016/j.jaad.2020.08.127
Publication status	Published - Apr-2021

Access to Document

10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practiceFinal publisher's version, 444 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Ariëns, L. F. M., van der Schaft, J., Spekhorst, L. S., Bakker, D. S., Romeijn, G. L. E., Kouwenhoven, T. A., Kamsteeg, M., Voorberg, A. N., Oosting, A. J., de Ridder, I., Sloeserwij, A., Haeck, I., Thijs, J. L., Schuttelaar, M. L. A., & de Bruin-Weller, M. S. (2021). Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. Journal of the American Academy of Dermatology, 84(4), e279-e280. https://doi.org/10.1016/j.jaad.2020.08.127

@article{ba6d1b871bc24fcc807d213b2b6eade3,

title = "Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry",

abstract = "Background Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0\% (standard deviation 33.2\%) and further decreased to –76.6\% (standard deviation 30.6\%) by week 52. A greater than or equal to 75\% improvement in the score was achieved by 59.9\% of individuals by week 16 and by 70.3\% by week 52. The most reported adverse effect was conjunctivitis (34\%). Limited patients (17; 8.1\%) discontinued dupilumab treatment. Limitations Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.",

author = "Ari{\"e}ns, \{Lieneke F.M.\} and \{van der Schaft\}, Jorien and Spekhorst, \{Lotte S.\} and Bakker, \{Daphne S.\} and Romeijn, \{Geertruida L.E.\} and Kouwenhoven, \{Tessa A.\} and Marijke Kamsteeg and Voorberg, \{Angelique N.\} and Oosting, \{Albert J.\} and \{de Ridder\}, Ilona and Annemieke Sloeserwij and Inge Haeck and Thijs, \{Judith L.\} and Schuttelaar, \{Marie L.A.\} and \{de Bruin-Weller\}, \{Marjolein S.\}",

year = "2021",

month = apr,

doi = "10.1016/j.jaad.2020.08.127",

language = "English",

volume = "84",

pages = "e279--e280",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "MOSBY-ELSEVIER",

number = "4",

}

Ariëns, LFM, van der Schaft, J, Spekhorst, LS, Bakker, DS, Romeijn, GLE, Kouwenhoven, TA, Kamsteeg, M, Voorberg, AN, Oosting, AJ, de Ridder, I, Sloeserwij, A, Haeck, I, Thijs, JL, Schuttelaar, MLA & de Bruin-Weller, MS 2021, 'Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry', Journal of the American Academy of Dermatology, vol. 84, no. 4, pp. e279-e280. https://doi.org/10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. / Ariëns, Lieneke F.M.; van der Schaft, Jorien; Spekhorst, Lotte S. et al.
In: Journal of the American Academy of Dermatology, Vol. 84, No. 4, 04.2021, p. e279-e280.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice

T2 - 52-Week results from the Dutch BioDay registry

AU - Ariëns, Lieneke F.M.

AU - van der Schaft, Jorien

AU - Spekhorst, Lotte S.

AU - Bakker, Daphne S.

AU - Romeijn, Geertruida L.E.

AU - Kouwenhoven, Tessa A.

AU - Kamsteeg, Marijke

AU - Voorberg, Angelique N.

AU - Oosting, Albert J.

AU - de Ridder, Ilona

AU - Sloeserwij, Annemieke

AU - Haeck, Inge

AU - Thijs, Judith L.

AU - Schuttelaar, Marie L.A.

AU - de Bruin-Weller, Marjolein S.

PY - 2021/4

Y1 - 2021/4

N2 - Background Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Limitations Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

AB - Background Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Limitations Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

U2 - 10.1016/j.jaad.2020.08.127

DO - 10.1016/j.jaad.2020.08.127

M3 - Article

SN - 0190-9622

VL - 84

SP - e279-e280

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. Journal of the American Academy of Dermatology. 2021 Apr;84(4):e279-e280. doi: 10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Abstract

Access to Document

Handle.net

Fingerprint

Cite this